ASH 2024 | Why does AML present a challenge for the development of successful CAR products?
In this video, Renier Brentjens, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, provides insight into why the development of successful CAR products presents more of a challenge in acute myeloid leukemia (AML) than in lymphoid malignancies. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Triumvira, Cargo Tx, CoImmune: Membership on an entity’s Board of Directors or advisory committees; BMS: Research Funding; BMS, Caribou, Sanofi: Other: licensed intellectual property to and collects royalties from; BMS, Atara Biotherapeutics Inc. and was a consultant for Triumvira, Cargo Tx, CoImmune: Consultancy.
